Maine Governor Signs Prescription Drug Bills Advocacy

Maine Governor Approves Price Transparency Drug Importation Laws

State also creates medicine affordability board

Getty Images Maine consumers can expect to see some relief from the high cost of prescription drugs under a series of bills Gov. Janet Mills signed into law on Monday. The four measures add to a growing number of laws enacted in in response to voters, who have made it clear that lowering the cost of prescription drugs continues to be a major issue for them. The package includes bills AARP has strongly supported as part of the organization's Stop Rx Greed campaign, launched this spring. "Mainers have told us time and again that we must address the rising costs of prescription medications,” says Lori Parham, AARP Maine state director. “Together, these bills will bring transparency to the process and start to address Rx costs for Maine families who often have to decide between food, medicine, and heating their homes in winter." The four bills Mills signed Monday include: A measure to establish a prescription drug importation program. This bill is modeled after the measure Vermont passed in 2018 and makes Maine the third state to approve such a measure this year. have signed similar bills. Like the other states, Maine must submit an application by May 1, 2020, to the federal Department of Health and Human Services to begin such a program. This legislation also directs state health officials to consider whether Maine's importation program may be developed in conjunction with other states. A provision to strengthen the state's drug transparency law to require brand-name pharmaceutical manufacturers to annually report any price increases of more than 20 percent and for generic manufacturers to report 20 percent price hikes for medicines that cost at least $10 per pill or other unit. A bill creating a Prescription Drug Affordability Board. This board would determine prescription drug spending targets and would suggest ways to lower drug costs through measures such as bulk purchasing, leveraging multistate purchasing, or negotiating specific rebate amounts. A measure to require pharmacy benefit managers (PBMs) to pass along to consumers all rebates they receive from drugmakers, and to direct PBMs to offer the cash price of a medicine to a consumer if it is lower than the patient's insurance copayment. "Our work isn't finished,” Parham says. “Maine leaders responded and worked together to . Now we need our members of Congress to do the same."

More on Prescription Drugs

Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures

Close In the next 24 hours, you will receive an email to confirm your subscription to receive emails related to AARP volunteering. Once you confirm that subscription, you will regularly receive communications related to AARP volunteering. In the meantime, please feel free to search for ways to make a difference in your community at Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.